Recent advances in ALS gene therapy, particularly targeting the TARDBP gene, have highlighted the potential of antisense RNAi and CRISPR/Cas9 method to mitigate the pathogenic effects of TARDBP mutations. Here, TARDBP is linked to amyotrophic lateral sclerosis.